RECRUITINGOBSERVATIONAL

Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.

About This Trial

To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..) 2. Age range of 18 to 75 years old 3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy Who Should NOT Join This Trial: 1. Age less than 18 years 2. Unable or unwilling to give willing to sign a consent form 3. Contra-indications to MRI 4. Electrical implants such as cardiac pacemakers or perfusion pumps 5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants 6. Ferromagnetic objects such as jewelry or metal clips in clothing 7. Pregnant subjects 8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..) 2. Age range of 18 to 75 years old 3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy Exclusion Criteria: 1. Age less than 18 years 2. Unable or unwilling to give informed consent 3. Contra-indications to MRI 4. Electrical implants such as cardiac pacemakers or perfusion pumps 5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants 6. Ferromagnetic objects such as jewelry or metal clips in clothing 7. Pregnant subjects 8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions

Treatments Being Tested

DEVICE

3D-MRE,MRI-PDFF

3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)

Locations (1)

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China